At page 33, line 6, replace "08/762,488" with --08/762,587--;

At page 37, line 5, replace "June 5" with --June 6--;

At page 43, line 27, replace "463,358" with --08/463,358--;

At page 43, line 27, replace "566,977" with --08/566,977--;

At page 47, line 6, replace "463,358" with --08/463,358--;

At page 47, line 6, replace "566,977" with --08/566,977--;

At page 98, line 1 of Table XVI, after "**Sequence**" insert --<SEQ. ID NO. 4>--;

At page 99, line 7, after "(an RGD peptide)" insert --<SEQ. ID NO. 8>--; and

At page 99, line 8, after "DELAEGGGVRGPRV" insert --<SEQ. ID NO. 9>.

In the Claims:

Please cancel claims 3, 4, 24 and 32.

Please amend claims 1, 2, 5, 6, 11, 13-16, 20, 23, 25, 27, 28, 30, 31, 33, 34 and 35.

Please add new claims 37-39.

---

1. (Twice amended) An oligonucleotide covalently attached to [a non-steroidal drug moiety] an arylpropionic acid that interacts with a protein.

B1

2. (Twice amended) The oligonucleotide of claim 1 wherein said [ligand] arylpropionic acid binds to said protein.

SUB C1

5. (Twice amended) The oligonucleotide of claim [3] 1 wherein said [drug moiety] arylpropionic acid is [aspirin, phenylbutazone,] ibuprofen, suprofen, fenbufen, ketoprofen, (*S*)-(+)-pranoprofen[, palmityl] or carprofen.

B2

6. (Twice amended) The oligonucleotide of claim [3] 5 wherein said [drug moiety] arylpropionic acid is ibuprofen.

B3

11. (Twice amended) The oligonucleotide of claim 1 further including a linking group attaching said [ligand] arylpropionic acid to said [oligomeric compound] oligonucleotide.

13. (Twice amended) The oligonucleotide of claim 1 [wherein said compound is an oligonucleotide] comprising a plurality of nucleosides connected by covalent internucleoside linkages.

B4

14. (Twice amended) The oligonucleotide of claim 13 wherein said internucleoside linkages are phosphodiester linkages.

15. (Twice amended) The oligonucleotide of claim 13 wherein said internucleoside linkages are phosphorothioate linkages.

16. (Twice amended) The oligonucleotide of claim 13 wherein said internucleoside

B4 linkages are non-phosphorus containing linkages.

20. (Twice amended) A method of increasing the concentration of an oligonucleotide in serum comprising the steps of:

B5 (a) selecting [a non-steroidal drug moiety] an arylpropionic acid that is known to bind to a serum protein;

(b) covalently attaching said [drug moiety] arylpropionic acid to said oligonucleotide to form a conjugated oligonucleotide; and

(c) adding said conjugated oligonucleotide to said serum.

SUB C2 B6 23. (Amended) The method of claim 20 wherein said [drug moiety] arylpropionic acid is [aspirin, warfarin, phenylbutazone,] ibuprofen, suprofen, fenbufen, ketoprofen, (*S*)-(+)-pranoprofen, or carprofen[, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic].

B7 25. (Amended) The method claim 20 wherein said [drug moiety] arylpropionic acid is ibuprofen.

B8 27. (Twice amended) A method of increasing the capacity of serum for an oligonucleotide comprising the steps of:

(a) selecting [a non-steroidal drug moiety] an arylpropionic acid that is known to bind to a serum protein;

(b) covalently attaching said [drug moiety] arylpropionic acid to said oligonucleotide to form a conjugated oligonucleotide; and

(c) adding said conjugated oligonucleotide to said serum.

B8

28. (Amended) The method of claim 27 wherein said serum protein is a protein having a binding site for said [drug moiety] arylpropionic acid.

B9

30. (Amended) The method of claim 27 wherein said serum protein is a protein having a binding site for said oligonucleotide and a binding site for said [drug moiety] arylpropionic acid; wherein said binding site for said oligonucleotide is distinct from said binding site for said [drug moiety] arylpropionic acid.

B10

31. (Twice amended) A method of increasing the binding of an oligonucleotide to a portion of the vascular system comprising the steps of:

(a) selecting [a non-steroidal drug moiety] an arylpropionic acid that is known to bind to a protein that resides, in part, in the circulating serum and in part in a non-circulating portion of the vascular system;

B11

(b) covalently attaching said [drug moiety] arylpropionic acid to said oligonucleotide to form a conjugated oligonucleotide; and

B11 (c) adding said conjugated oligonucleotide to said vascular system.

SUB B13 33. (Amended) The method of claim 31 wherein said [drug moiety] arylpropionic acid is [aspirin, phenylbutazone,] ibuprofen, suprofen, fenbufen, ketoprofen, (*S*)-(+)-pranoprofen[, palmityl] or carprofen.

B12

34. (Amended) The method claim 31 wherein said [drug moiety] arylpropionic acid is ibuprofen.

35. (Twice amended) A method of promoting cellular uptake of an oligonucleotide in a cell comprising the steps of:

B13 (a) selecting a protein that resides on the cellular membrane and extends, at least in part, on the external side of said membrane;

(b) selecting [a drug moiety] an arylpropionic acid that is known to bind to said protein;

(c) covalently attaching said [drug moiety] arylpropionic acid to said oligonucleotide to form a conjugated oligonucleotide; and

(d) exposing said cell to said conjugated oligonucleotide.

37. (New) The oligonucleotide of claim 10 wherein said serum protein is human serum albumin.

B14